NexGel (NXGL)
Manufactures customizable hydrogels and sells consumer, white-label, and licensed surgical biomaterials.
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
LANGHORNE, Pa. , Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL") today announced a series of leadership, governance and strategic initiatives designed to strengthen operational execution, improve liquidity, and enhance long-term shareholder value. The actions include the appointment of Brian Kieser as Interim Chief Executive Officer and the formation of a Special Committee for Strategic Review and Value Creation.
NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
LANGHORNE, Pa. , June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Planet MicroCap Conference on June 16 - 18, 2026, in Las Vegas, NV.
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration
The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control The study was published in Lasers in Surgery and Medicine, 2026 LANGHORNE, Pa.
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa. , May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL.
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
Management Will Host a Conference Call at 12:00 P. M. ET on the Same Day LANGHORNE, Pa. , May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2026 ended March 31, 2026, on Friday, May 15, 2026.
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa.
NEXGEL Appoints Ian Blackman as Chief Financial Officer
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer.
NexGel Calls Celularity Wound Deal “Transformational,” Eyes $35M Revenue and EBITDA Profitability
NexGel (NASDAQ: NXGL) used a shareholder update conference call to discuss the closing of its acquisition of Celularity's Degenerative Wound segment, a move CEO Adam Levy described as "transformational" as the company shifts into what he called a more scalable and diversified medical technology business. Acquisition details and new BioNX Surgical division Levy said the acquired
NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript
NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
Transaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Forms BioNX Surgical, a division of NEXGEL LANGHORNE, Pa.
Financial Comparison: NexGel (NASDAQ:NXGL) and Pressure BioSciences (OTCMKTS:PBIO)
NexGel (NASDAQ: NXGL - Get Free Report) and Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations. Institutional and Insider Ownership 2.2% of NexGel shares
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET.
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET.
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 15, 2026, at 4:30 P.M. ET.
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc.
NexGel (NXGL) Expected to Announce Earnings on Monday
NexGel (NASDAQ: NXGL - Get Free Report) is expected to be releasing its Q4 2025 results after the market closes on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $3.24 million for the quarter. Individuals can check the company's upcoming Q4 2025 earning summary page for the
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing
NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence
LANGHORNE, Pa. , Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.